-
16 May 2025 23:06:57
- Source: Sharecast
Grant of options
Oxford, UK - 16 May 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, announces that on 16 May 2025, nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the OXB 2024 Long Term Incentive Plan ("LTIP") and OXB 2024 Deferred Bonus Plan ("DBP").
2025 Grants
|
Type
|
Name of individual |
Title |
Number of share options granted under the plans prior to 2025 award |
Number of share options granted under 2025 award |
Total share options subsequently held under plans |
Percentage of current issued share capital under plans |
|
|
LTIP |
Frank Mathias |
Chief Executive Officer |
580,291 |
350,204 |
930,495 |
0.88% |
|
|
DBP |
Frank Mathias |
Chief Executive Officer |
930,495 |
70,803 |
1,001,298 |
0.94% |
|
|
LTIP |
Lucinda Crabtree |
Chief Financial Officer |
170,113 |
201,095 |
371,208 |
0.35% |
|
|
DBP |
Lucinda Crabtree |
Chief Financial Officer |
371,208 |
15,733 |
386,941 |
0.36% |
|
|
LTIP |
Natalie Walter |
Group General Counsel |
201,987 |
73,360 |
275,347 |
0.26% |
|
|
DBP |
Natalie Walter |
Group General Counsel |
275,347 |
11,448 |
286,795 |
0.27% |
|
|
LTIP RSU |
Natalie Walter |
Group General Counsel |
286,795 |
14,204 |
300,999 |
0.28% |
|
|
LTIP |
Sebestien Ribault |
Chief Business Officer |
125,309 |
80,029 |
205,338 |
0.19% |
|
|
DBP |
Sebestien Ribault |
Chief Business Officer |
205,338 |
14,879 |
220,217 |
0.21% |
|
|
LTIP RSU |
Sebestien Ribault |
Chief Business Officer |
220,217 |
15,495 |
235,712 |
0.22% |
|
|
LTIP |
Lisa Doman |
Chief People Officer |
140,453 |
62,585 |
203,038 |
0.19% |
|
|
DBP |
Lisa Doman |
Chief People Officer |
203,038 |
10,693 |
213,731 |
0.20% |
|
|
LTIP RSU |
Lisa Doman |
Chief People Officer |
213,731 |
12,118 |
225,849 |
0.21% |
|
|
LTIP |
Thierry Cournez |
Chief Operating Officer |
118,007 |
74,132 |
192,139 |
0.18% |
|
|
DBP |
Thierry Cournez |
Chief Operating Officer |
192,139 |
12,336 |
204,475 |
0.19% |
|
|
LTIP RSU |
Thierry Cournez |
Chief Operating Officer |
204,475 |
14,353 |
218,828 |
0.21% |
|
|
LTIP |
Kyriacos Mitrophanous |
Chief Innovation Officer |
232,084 |
70,699 |
302,783 |
0.29% |
|
|
DBP |
Kyriacos Mitrophanous |
Chief Innovation Officer |
302,783 |
12,852 |
315,635 |
0.30% |
|
|
LTIP RSU |
Kyriacos Mitrophanous |
Chief Innovation Officer |
315,635 |
13,689 |
329,324 |
0.31% |
|
|
LTIP |
Mark Caswell |
Site Head of UK Operations |
127,896 |
79,168 |
207,064 |
0.20% |
|
|
LTIP RSU |
Mark Caswell |
Site Head of UK Operations |
207,064 |
15,329 |
222,393 |
0.21% |
|
|
LTIP RSU |
Sabine Sydow |
Chief of Staff |
20,115 |
9,780 |
29,895 |
0.03% |
|
|
LTIP RSU |
Stephanie Colloud |
Site Head of France Operations |
- |
12,634 |
12,634 |
0.01% |
|
The Remuneration Committee has determined that EBITDA margin and revenue growth are the key metrics aligned with OXB's growth strategy, relevant to LTIP grant only. Details of the targets for the EBITDA margin and revenue growth measures are included in the 2024 Directors' Remuneration Report.
The Notification of Dealing Forms set out below, which all represent initial notifications in respect of the grants mentioned above, are provided in accordance with the requirements of the EU Market Abuse Regulation.
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Frank Mathias |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Executive Officer
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 350,204 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Frank Mathias |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Executive Officer
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 DBP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 70,803 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Lucinda Crabtree |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Financial Officer
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 201,095 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Lucinda Crabtree |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Financial Officer
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 DBP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 15,733 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Natalie Walter |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
General Counsel |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 73,360 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Natalie Walter |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
General Counsel |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 DBP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 11,448 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Natalie Walter |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
General Counsel |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 14,204 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Sebastien Ribault |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Business Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 80.029 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Sebastien Ribault |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Business Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 DBP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 14,879 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Sebastien Ribault |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Business Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 15,495 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Lisa Doman |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief People Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 62,585 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Lisa Doman |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief People Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 DBP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 10.693 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Lisa Doman |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief People Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 12,118 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Thierry Cournez |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Operating Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 74,132 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Thierry Cournez |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Operating Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 DBP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 12,336 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Thierry Cournez |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Operating Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 14,353 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Kyriacos Mitrophanous |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Innovation Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 70,699 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Kyriacos Mitrophanous |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Innovation Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 DBP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 12,852 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Kyriacos Mitrophanous |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Innovation Officer |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 13,689 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Mark Caswell |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Site Head of UK Operations |
||||
|
b) |
Initial notification/ amendment |
Initial notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
79,168
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Mark Caswell |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Site Head of UK Operations |
||||
|
b) |
Initial notification/ amendment |
Initial notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
15,329
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Sabine Sydow |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief of Staff |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 9,780 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Stephanie Colloud |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Site Head of France Operations |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2025 LTIP RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 12,634 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2025-05-16 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
-Ends-
Enquiries:
OXB:
Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.